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Abstract
A symposium on kidney stones and mineral metabolism held on December 2017 in Brussels, Belgium was the first interna-
tional multidisciplinary conference of the International Collaborative Network on Kidney Stones and Mineral Metabolism. 
This meeting addressed epidemiology, underlying pathophysiological mechanisms, genetics, pathological, as well as clinical 
and research topics. The participants included clinicians and recognized experts in the field from Europe and the United 
States interacted closely during the symposium which promoted a chance to explore new frontiers in the field of kidney stone 
disease. This manuscript summarizes some of the major highlights of the meeting.
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Introduction
Kidney stone disease (KSD) is a common disorder of min-
eral metabolism worldwide [1]. Its prevalence is rising, 
causing significant morbidity with a considerable eco-
nomic impact, in particular among older adults compared 
to younger adults [2–4]. According to the latest estimate 
from 2007 to 2010 from the National Health and Nutrition 
Examination Survey (NHANES), the overall prevalence 
of kidney stones (KS) in the United States was 10.6% in 
men and 7.1% in women [5]. Therefore, 1 in 11 individu-
als in the United States had a history of kidney stones, in 
contrast to the previous estimate of 1 in 20 in the United 
States population from the late 1980s [5]. A similar rise 
in prevalence was detected in many European countries 
[6, 7].
Conditions associated with metabolic syndrome are risk 
factors for KS formation in general, and uric acid stones 
in particular [5, 8–10]. However, calcium-based stones 
remain by far the most commonly encountered KS [8, 10, 
11], and hypercalciuria is the most frequently identified 
metabolic abnormality in calcium stone formers [9, 12].
In recent years, KS has emerged as a multi-systemic 
disorder. In general, kidney stone formers independent 
of their stone composition have twice the risk of CKD 
compared to non-stone formers [13–15]. Nephrolithiasis 
can impair kidney function with complications such as 
obstruction, infection, or secondary to urological proce-
dures, or may be primary in nature with parenchymal dam-
age induced by the underlying conditions leading to stone 
formation such as monogenic disorders, nephrocalcinosis, 
and primary and secondary hyperoxaluria [16].
The International Collaborative Network on Kidney 
Stones and Mineral Metabolism (ICNKSMM) held in 
Belgium in December 2017 (http://www.chu-brugm ann.
be/en/news/20171 207-kidne yston es.asp) bridged together 
practitioners and academicians in the field to develop a 
common program dedicated to understanding the under-
lying pathophysiologic mechanisms, genetics, as well as 
diagnosis and management of the population of stone 
formers. Another major goal of the Symposium was to 
cultivate interest among young physicians to engage in 
kidney stone research in the future.
Genetics of nephrocalcinosis 
and nephrolithiasis
The etiology of the most frequent forms of calcium 
stones nephrolithiasis is multifactorial; involving nutri-
tional, environmental, and polygenic genetic determinants 
according to Prof Giovanni Gambaro from Nephrology 
and Dialysis Division, Gemelli University Hospital from 
Italy. Nephrolithiasis is a common condition, and genetics 
play a central role in defining the metabolic “milieu” from 
which KS may form [17–19]. There is a clustering of KS 
in nearly 50% of KSF families. Family history of KSD is 
significantly associated with more complex presentation 
and higher recurrence rate in idiopathic calcium KSF [20].
KS are frequently associated with urinary metabolic 
disorders including as hypercalciuria (40 to 75%), hyper-
oxaluria (5 to 20%), hyperuricosuria (~ 10%) and hypoci-
traturia (20%). Idiopathic hypercalciuria and calcium stone 
disease is indeed a complex (multifactorial and polygenic) 
[21] condition resulting from dietary – environmental 
interactions in a genetically predisposed subject. Herit-
ability and environment effects have been reported in 56% 
and 44% respectively [17]. Genome wide association stud-
ies (GWAS) in Iceland and Japan have found 8 genes that 
modulate the risk but are not necessarily directly respon-
sible for KSD [22, 23]. Mendelian disorders causing renal 
stones and nephrocalcinosis involve mutations in the genes 
of the calcium sensing receptor, soluble adenylyl cyclase, 
vitamin D receptor, claudins, chloride channels, sodium/
phosphate transporter, carriers involved in the pathogen-
esis of distal renal tubular acidosis, genes involved in renal 
morphogenesis, and medullary sponge kidney, as well as 
many others (Table 1, adapted from [24–27]) [28].
Recent genetic studies led by a single group using exon 
sequencing of selected gene panels and whole exome 
sequencing suggested that monogenic disorders may be 
more common than previously suspected in kidney stone 
disease [29–31]. In fact, 14 monogenic genes caused 
nearly 15% of kidney stones in a population of 26 consecu-
tive recurrent KSF [29]. However Prof Gambaro empha-
sized the high number of pediatric cases and the potential 
for some selection bias in these studies.
In patients with primary hyperoxaluria in whom no 
mutation is identified in the coding regions of the three 
known genes responsible for primary hyperoxaluria (types 
1, 2, and 3), testing for mutations in non-coding regions 
(promoter, introns) or in other gene encoding proteins 
of oxalate metabolism has been suggested in the further 
explorations of phenotype-genotype relationships [32]. 
Diagnosing genetic forms of nephrolithiasis is crucial for 
personalized medicine in stone formers [33].
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Epidemiology, morphoconstitutional 
classification and its correlates 
with pathogenesis and epidemiology 
of kidney stones
The incidence of KSD has progressively increased dur-
ing the past 30  years in most industrialized countries 
underlined Prof Michel Daudon, head of the Centre de 
Recherches et d’Informations Scientifiques et Techniques 
Appliquées aux Lithiases (Laboratoire CRISTAL) since 
1986 and responsible for a National Quality Control Pro-
gram on Stone Analysis in France since 1990.
Urolithiasis affects between 5 and 12% of the general 
population and two times more often males than females. 
However, a trend to a decrease of the male-to-female 
ratio has been recently reported in some countries. Cal-
cium oxalate (CaOx) stones are the most common uri-
nary calculi, accounting for more than 70% of all stones 
in large series published from the beginning of the 1980s. 
However, differences are found in chemical composition 
and crystalline phases according to the patient’s gender: 
calcium phosphate is more frequent in female (27.1 vs. 
9.7% in males, p < 0.0001) while CaOx is more frequent 
in male patients (74.9% vs 57.9% in females, p < 0.0001). 
Stone composition also varies with age in both genders, 
as a consequence of changes in lithogenic risk factors. For 
example, uric acid (UA) stones are infrequent in young 
stone formers and become the prevalent category in old-
est patients in relation to the increase of body mass index 
and of the type 2 diabetes prevalence. By contrast, among 
CaOx stones, weddellite is more common in younger than 
in older patients.
Prof Daudon highlighted that physical methods, mainly 
X-ray diffraction (XRD) and Fourier transform infrared 
spectroscopy (FTIR) reliably identify specific forms of 
nephrolithiasis involving non-calcium components such 
as cystine, purines or drugs [34, 35]. For calcium stones, 
these methods provide information on chemical (CaOx 
and/or calcium phosphate) and crystalline phases, which 
appears more clinically relevant. However, the same 
crystalline phase may result from a variety of pathologi-
cal conditions. Stone analysis combining morphologi-
cal examination followed by XRD or FTIR analysis of 
the core, middle layers, and surface of calculi provides a 
more complete understanding of etiologic diagnosis than 
compositional analysis alone. Using this morphological 
method, stones may be classified into 7 types subdivided 
in 22 subtypes (Table 2 adapted from [36]) [37]. While 
crystalline phases may point out the main metabolic dis-
orders involved in stone formation, morphological type is 
highly suggestive for specific lithogenic processes. Thus, 
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present as five different morphologies: among them, type 
Ia is often related to moderate hyperoxaluria due to low 
diuresis or intake of oxalate-rich food. By contrast, type Ic 
is pathognomonic of genetic heavy hyperoxaluria [38] and 
type Ie is a marker for enteric hyperoxaluria [34]. Sequen-
tial analysis may reveal changes with time in the factors 
involved in stone formation.
Prof Khashayar Sakhaee from the United States under-
lined the association between changes in kidney stone com-
position, with the varying demographics and biochemical 
profiles in a retrospective study in the Unites States from 
1980 to 2015 involving 1516 KS patients. This study showed 
the proportion of UA stones increased from 7 to 14% [8]. 
The proportion of females with KS increased over time but 
the increase in females was more significant among calcium 
stone formers. Age and body mass index increased with time 
in both UA and calcium stone formers [39, 40]. However, 
UA stone formers were consistently older and had a higher 
body mass index and lower urinary pH than calcium stone 
formers [8]. Hyperuricosuria itself or concomitantly with 
hypocitraturia, hyperoxaluria and hypercalciuria could lead 
to hyperuricosuric calcium nephrolithiasis [41]. A separate 
retrospective study of 2132 KS patients from Europe demon-
strated that obese and overweight KSF exhibited higher uri-
nary UA, urinary sodium, urinary calcium and significantly 
lower urinary pH [9]. In addition to increased prevalence of 
metabolic syndrome in the past decades, global warming and 
greater urbanization are predicted to contribute to increased 
risk of nephrolithiasis in the future [42]. Finally, the protec-
tive impact of dietary approaches to KS prevention is more 
apparent in single stone formers, whereas anti-lithogenic 
drugs are more effective for recurrent KSF [43].
Cell biology of nephrocalcinosis 
and nephrolithiasis
Considering the increased incidence of KSD Benjamin Ver-
vaet, cell biology researcher from Belgium presented the 
interactions between crystals and renal tubular epithelial 
cells, and the role of the renal tubular epithelium both in 
the onset and outcome of early stages of KSD. Like any 
other bio-mineralization process, nephrocalcinosis and 
nephrolithiasis are manifestations of a complex interplay 
between crystals physicochemical characteristics and cell 
biology [44]. This century, it has become clear that nephro-
calcinosis and nephrolithiasis are to be considered two inde-
pendent entities. In depth microscopic and histopathologic 
research was crucial to differentiate between intratubular and 
interstitial nephrocalcinosis. On the one hand, intratubular 
nephrocalcinosis develops as a consequence of phenotypi-
cal changes of the renal tubular epithelial cells, which, due 
to prior injury, gain crystal-binding properties [45]. On the 
other hand, interstitial nephrocalcinosis starts as a de novo 
crystal formation process in the interstitium and is thought 
to be the result of local patho-physiological disturbances in 
proper ion and/or acid-base handling [46]. Both forms of 
nephrocalcinosis can progress to nephrolithiasis, however 
only under certain specific conditions. In addition, being 
evolutionary challenged, the kidney displays several crys-
tallization defense mechanisms. At least in the condition 
of intratubular nephrocalcinosis, kidney is even capable of 
actively removing and dissolving retained crystals in a cell-
driven process [47]. Although it is clear that the kidney has 
still not revealed all its cell biological secrets, concerted 
research actions has led to the development of solid etio-
logical concepts.
Determinants of Randall’s plaque formation
The mechanism of heterogeneous nucleation at the tip of 
the renal papilla that give birth to CaOx stones was detailed 
by Prof Emanuel Letavernier from Service des explorations 
fonctionnelles, Tenon Hospital in Paris, France. He under-
lined that the genetic and environmental determinants of 
Randall’s plaque formation are still partly described.
Indeed, KS were for the first time described to originate 
from calcium phosphate plaques growing in the interstitial 
tissue, breaking the urothelium and then promoting mono-
hydrate CaOx crystal aggregation at their contact over 6 
decades ago. The development of endoscopic procedures 
allowing plaque visualization renewed interest in Randall’s 
plaque. In parallel, a dramatic increase in the proportion 
of CaOx stones grown on Randall’s plaque during the past 
decades has been reported in France [48].
Hypercalciuria is probably a major risk factor for Ran-
dall’s plaque formation. Increasing sensitivity to vitamin D 
in KSF presenting with Randall’s plaque has been proposed 
[49, 50]. Calcification inhibitors might be essential to pre-
vent Randall’s plaque development [50, 51]. The identifica-
tion of environmental factors and genetic polymorphisms 
promoting Randall’s plaque formation have emerged as 
essential to eventually prevent or slow down plaque forma-
tion in predisposed children and young adults [52].
Pathology of crystals‑induced nephropathy
Sustained exposure of tubular epithelium to crystals induce 
a lesion classified as crystal induced nephropathy or crys-
talline nephropathy (CN), term applied to patterns of renal 
injury sharing the distinctive finding of crystals within 
tubules and/or interstitium. Crystal nephropathy is not only 
related to the crystals deposition as detailed Prof Isabelle 
Brochériou from Pathology Department at Pitié-Salpêtrière 
Journal of Nephrology 
1 3
Hospital, Sorbonne Université and INSERM Unit U1155 in 
Paris, France. Indeed, based on the clinical setting in which 
they are formed, or on the composition of the crystals, CN 
is divided into the following 4 categories: (1) CN related 
to dysproteinemia, (2) drug-induced CN, (3) CN related to 
calcium deposition, and (4) other metabolic and genetic CN 
forms.
The dysproteinemia-related CN includes light chain cast 
nephropathy, also known as myeloma cast nephropathy, 
which is the most common dysproteinemia-related renal dis-
ease [53, 54]. Crystalline nephropathy may develop during 
the use of drugs (ceftriaxone [55]), sulfadiazine [56], acy-
clovir [57], triamterene [58], atanazavir [59], and others that 
are excreted by the kidney (see details in recent review [60]). 
Calcium crystals CN is characterized by abundant tubular 
and interstitial deposits of calcium phosphate or CaOx 
crystals, easily distinguished by their tinctorial properties. 
Hypercalcemia is the most common condition associated 
with subsequent nephrocalcinosis. Enteric hyperoxaluria 
is frequently found in CaOx nephropathy, which can also 
be seen in severe hereditary enzymatic defects known as 
the primary hyperoxaluria [61]. Some inherited (cystinosis, 
2,8-dihydroxyadenine deficiency, primary hyperoxaluria) 
or acquired metabolic disorders are responsible for crys-
talline nephropathies [62–64]. Careful clinical-pathologic 
correlation with concomitant identification of urine crystals 
Fig. 1  Representative photomicrographs of crystalline nephropa-
thies. Atazanavir-induced nephropathy: a Foreign-body type reac-
tion (arrow) surrounding the crystal (star). PAS staining, original 
magnification × 200. b Cristals (arrows) present on typical frozen 
section without staining, original magnification  ×  400. c Birefrin-
gent, intratubular and intracellular crystals observed under polarized 
light microscopy analysis, original magnification  ×  400. Crystal-
line nephropathy due to 2,8-dihydroxyadeninuria: d Several yellow-
brownish crystals (arrow) within the cytoplasm of tubular epithelial 
cells and foreign-body type reaction within interstitium surrounding 
the crystal aggregates. Hematoxylin & eosin staining, original mag-
nification  ×  400. e  Polarized light microscopy showed the crystals 
to be strongly birefringent, demonstrating a radial orientation with a 
variable appearance, including needle, ring- and spherically-shaped 
aggregates (so-called Maltese cross pattern was not observed in this 
case). Original magnification × 400. f Crystals are negatives on Van 
Kossa staining used for identification of calcium deposits, Original 
magnification × 200. Monoclonal gammopathy of renal significance: 
g Proximal tubular lesions were seen with focal atrophy (star) and 
brush border disappearance (arrow). PAS staining, original magnifi-
cation × 200. h Crystals were detected in the cytoplasm of interstitial 
histiocytes (arrow) on toluidine blue staining of semithin sections. i 
Numerous needle-shaped crystals (arrow) in the cytoplasm of altered 
epithelial cells (crystalline inclusions were observed in the cytoplasm 
of proximal tubular cells, not shown). Electron microscopy study. 
Kindly provided by Prof Isabelle Brochériou from Pathology depart-
ment, Pitié-Salpêtrière hospital, INSERM Unit U1155, Paris, France
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(cristalluria) is fundamental in the interpretation of CN etiol-
ogy [65, 66]. Adequate identification of the causative patho-
logical condition(s) improves the correctness of diagnostic 
(Fig. 1) allowing a more personalized therapeutic approach 
that is essential to reduce the risk of kidney function decline 
[62, 64, 66].
Kidney stones as a multi‑systemic illness
If uncontrolled, CN leads to progressive loss of glomeru-
lar filtration rate and development chronic kidney disease 
(CKD). This long-term complication of KSD was presented 
by Prof Agnieszka Pozdzik from Kidney Stone Clinic, Neph-
rology and dialysis clinic at Hospital Brugmann, Université 
Libre de Bruxelles in Brussels, Belgium.
Considering that CKD has become a global public health 
problem with serious social and economic effects from pre-
mature morbidity to death, nephrologists are attentive to 
identify all possibly treatable CKD risk factors, and KSD 
is one of them [67].
Indeed, growing evidence demonstrates a consistent 
relationship between nephrolithiasis and the development 
of CKD, and leading to end-stage renal disease (ESKD) in 
more than 3% of cases [68–70]. Moreover, recent epide-
miological studies have shown the association of KSD with 
cardio-vascular disorders, arterial hypertension, obesity, 
diabetes mellitus, metabolic syndrome that are well-recog-
nized risk factors for CKD (Fig. 2) [71]. Regardless of the 
associated co-morbid conditions, KSD has been shown to 
be an independent risk factor in the development of CKD 
[15]. Definitely, KSF have nearly twice-risk to develop CKD 
compared with patients without stones. Urolithiasis and its 
complications or conditions associated with kidney stones 
have been reported in 5.1% of all ESKD cases [72].
Other risk factors associated with CKD identified in KSF 
include: existing kidney functional impairment, recurrent 
urinary tract infections with kidney stones of particular 
compositions including struvite, UA stones, symptomatic 
stones, solitary kidney, neurogenic bladder, renal or urinary 
tract malformations and ileal diversion, malabsorptive bowel 
conditions and some monogenic diseases responsible for 
nephrolithiasis and/or nephrocalcinosis, especially in chil-
dren (Table 1) [73].
Given the risk of KS recurrence, high morbidity, the 
necessity of endo-urological or surgical interventions, early 
diagnosis and specialized management of KSD is indicated 
[74]. Awareness is essential to rapidly identify the pro-lith-
ogenic metabolic abnormalities, assess the coexistence of 
renal and/or cardiovascular complications with the aim of 
controlling KSD and slowing down the CKD progression 
with adequate treatment [75, 76]. At the present time the 
evaluation of the global risk of developing CKD/ESKD and 
of related metabolic disorders during the workup of patients 
with KS is mandatory (Fig. 3). In addition, the ultrasound 
scans exploration of KS and related complications such as 
obstructive nephropathy or urinary tract infection need to be 
adapted case by case during the follow [77].
Calcium metabolism and kidney stones
In their presentations, Dr. Naim Maalouf and Dr. Khash-
ayar Sakhaee from the Department of Internal Medicine and 
the Charles and Jane Pak Center for Mineral Metabolism 
and Clinical Research at the University of Texas South-
western Medical Center, in Dallas, Texas, USA, reviewed 
normal calcium homeostatic mechanisms and pathophysi-
ologic mechanisms underlying hypercalciuria. Intrinsic 
determinants of urinary calcium excretion include factors 
that impact the filtered load of calcium (via intestinal cal-
cium absorption and bone formation/ resorption), and oth-
ers that alter renal calcium handling at various segments of 
the nephron. Extrinsic factors that alter calcium handling 
involve dietary and other lifestyle factors (including intake 
of calcium, sodium, animal proteins, etc..), and medications 
that impact calcium metabolism and ultimately the risk of 
nephrolithiasis.
Calcium KSD is the second most prevalent kidney disease 
after arterial hypertension. Approximately 80% of calcium 
kidney stones are CaOx, with a small percentage (15%) of 
calcium phosphate. The pathophysiologic mechanisms for 
calcium KS are complex and diverse [78, 79]. However, 
both hypercalciuria and hyperoxaluria play a major role in 
the formation of calcium oxalate stones. Hypercalciuria is 
a heterogeneous disorder and is commonly due to enhanced 
Fig. 2  Interrelationships between kidney stones disease, cardiovas-
cular disease, systemic metabolic disorders, bone metabolism and 
chronic kidney disease
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intestinal calcium absorption which has been demonstrated 
to be 1,25(OH)2 vitamin D-dependent or independent [80]. 
A previous study showed that absorptive hypercalciuria is 
due to increased production of 1,25(OH)2D. However, until 
recently the underlying mechanism of overproduction of 
1,25(OH)2D was not fully elucidated. Recently, loss-of-
function mutations in CYP24A1 in patients with idiopathic 
infantile hypercalciuric nephrolithiasis has been shown to be 
a responsible mechanism in a subset of this population [81].
With increasing body mass index over the past 3-½ dec-
ades, urinary oxalate excretion has gradually and signifi-
cantly increased [8]. One important underlying mechanism 
has been linked to differences in the decreasing preva-
lence of Oxalobacter formigenes (OF) colonization among 
patients with recurrent calcium stone disease [82]. This 
gram-negative obligate anaerobe bacterium found in gas-
trointestinal tracts of humans uses oxalate as its sole source 
of energy [83]. A metabolic study performed in OF colo-
nized and non-colonized stone formers demonstrated sig-
nificantly higher urinary oxalate among the non-colonized 
stone-forming population. In addition, an inverse relation-
ship was detected between the number of stone episodes 
and OF colonization rate [84]. Improved understanding of 
this pathogenetic pathway will open the door to the new 
pharmacological approaches using probiotic therapy with 
OF, oxalate degrading enzymes, and/or recombinant proteins 
to upregulate of oxalate secretion into the intestinal lumen. 
The link between overweight, and obesity with alteration in 
colonization with OF is in part related to the risk of hyper-
oxaluria in obese subjects. Another potential mechanism 
has been attributed to the involvement of inflammatory 
processes caused by obesity resulting in increasing intestinal 
permeability and enhanced oxalate absorption.
Calcium stone formers are known to exhibit an exagger-
ated postprandial rise in urine calcium excretion compared 
with non-stone-forming subjects, and insulin has been pro-
posed to mediate this difference. However, the rise in uri-
nary calcium associated with euglycemic hyperinsulinemia 
has shown not to be different between KSF and non-stone-
forming controls. Thus, insulin is unlikely to play a role in 
the pathogenesis of hypercalciuria in this population. Lastly, 
a short-term study has shown that mechanism(s) other than 
acid load accounts for hypercalciuria induced by a high pro-
tein diet. This study will open new insights into the potential 
role of aromatic amino acids in regulating calcium sensor 
in gastrointestinal tract and kidney in the pathogenesis of 
protein-induced hypercalciuria [85, 86].
Primary hyperparathyroidism: diagnosis 
and treatment
The prevalence of primary hyperparathyroidism (HPT) 
varies between 1 and 20/1000 [87] underlined Prof Jean-
Jacques Body, from Internal Medicine department at Brug-
mann Hospital, and head consultant for Bone diseases and 
endocrinology at Institute Bordet (Cancer Centre at the 
«Université Libre de Bruxelles», Brussels, Belgium).
HPT is nowadays most often asymptomatic and the 
diagnosis is made by chance or done during the workup 
of calcium nephrolithiasis or osteoporosis [88]. The inci-
dence of nephrolithiasis has been considerably lowered 
Fig. 3  Proposed evaluations 
for diagnosis and management 
of patients with kidney stones. 
CKD chronic kidney disease, 
HTA arterial hypertension, KS 
kidney stone, KSD kidney stone 
disease
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but is still the most frequent complication of HPT (17%) 
whereas osteoporotic fractures are now present in less than 
2% of the cases. Hypercalcemia and an elevated parathy-
roid hormone (PTH) concentration, or at least a PTH level 
in the upper part of the normal range, generally point to a 
diagnosis of HPT. Additional tests include an evaluation 
of renal function, vitamin D measurement, determination 
of 24-h urinary calcium and bone densitometry [89].
Besides symptomatic HPT, recent recommendations for 
surgery include age less than 50, serum calcium at least 
1 mg/dL above the upper limit of normal, calculated cre-
atinine clearance < 60 ml/min, 24-h urinary calcium higher 
than 400 mg/day (or 10 mmol/day), and increased stone 
risk by biochemical stone risk analysis, presence of neph-
rolithiasis or nephrocalcinosis, and clinical or confirmed 
osteoporosis [90, 91]. Parathyroid scintigraphy coupled 
with computed tomography is the best preoperative locali-
zation technique. In the hands of an experienced surgeon, 
the success rate of elective surgery is 96–99% and the rate 
of permanent complications is lower than 1–2% [92].
Type 2 diabetes and calcium nephrolithiasis
An increased prevalence of nephrolithiasis reported in 
patients with type 2 diabetes has been approached by Pr 
Michel Daudon. Because insulin resistance, characteristic 
of the metabolic syndrome and type 2 diabetes, results in 
lower urine pH through impaired kidney ammoniagenesis, 
and since a low urine pH is the main factor of UA stone 
formation, it was hypothesized that type 2 diabetes should 
favor the formation of UA stones [93–96]. An abundant 
literature has extensively confirmed that around 30 to 40% 
of type 2 diabetic stone formers produce UA stones. While 
the prevalence of UA stones was significantly increased in 
French cohort of diabetic patients, Pr Daudon conversely 
found a significant decrease in calcium phosphate stones 
and weddellite stones in such patients [93]. By contrast, 
the proportion of whewellite calculi was not reduced, 
which suggests that hyperoxaluria could be another meta-
bolic factor involved in stone formation in type 2 diabetes 
[97]. In addition, the morphology of whewellite stones 
suggest highs levels of urinary oxalate. Actually, urinary 
oxalate excretion was found significantly increased in dia-
betic patients and it was recently reported that glyoxylate, 
one of the main precursor of oxalate synthesis, was early 
increased in blood of type 2 diabetic patients [98, 99]. 
The proposed link between glyoxylate and type 2 diabetes 
could be AGXT2, an hepatic enzyme that may be down-
regulated by loss of function of HNF4α (hepatic nuclear 
factor 4α) [100].
Nephrolithiasis from vitamin D and calcium 
supplementation
Calcium and vitamin D supplements are widely used for 
the prevention and treatment of osteoporosis. These sup-
plements significantly increase urinary calcium, poten-
tially predisposing to calcium nephrolithiasis said Dr 
Naim Maalouf. In several observational and randomized 
prospective studies, including the large Women’s Health 
Initiative randomized clinical trial, supplemental calcium 
and vitamin D significantly increased the incidence of 
nephrolithiasis [101]. Calcium supplement type (calcium 
carbonate vs. calcium citrate), dose, and timing of intake, 
all appear to influence KS risk. In contrast to calcium sup-
plements, higher dietary calcium intake appears to lower 
the risk of kidney stone formation in several observational 
studies [102–104]. The impact of vitamin D supplementa-
tion (without calcium) has been studied in small prospec-
tive studies and found to be safe for the average KSF with 
vitamin D deficiency [105]. However, a subset of calcium 
stone formers may exhibit worsening hypercalciuria upon 
vitamin D supplementation [106]. In his presentation Dr 
Maalouf reviewed the epidemiology and pathophysiologic 
mechanisms by which calcium and vitamin D supplements 
impacts nephrolithiasis risk, and outlined a framework to 
employ when considering calcium and/or vitamin D sup-
plementation in nephrolithiasis patients (Table 3).
Calcium oxalate stone morphology 
and urine biochemistry in malabsorptive 
bowel diseases
In bowel diseases, a malabsorption syndrome may result 
from intestinal diseases or frequently from gastric bypass 
surgery prescribed as treatment of morbid obesity [107]. 
The prevalence of CaOx stones and the renal prognosis 
of patients undergoing a bariatric surgery or affected by 
bowel diseases is a matter of concern nowadays underlined 
Prof Emmanuel Letavernier. Indeed, low diuresis, result-
ing from reduced water intake and water loss (diarrhea), 
is a common risk factor of kidney stones. Patients with 
colon resection and ileostomy form uric acid stones, attrib-
uted to bicarbonate loss in the ileostomy and low urine 
pH. Patients with malabsorption syndrome and functional 
colon are affected by calcium oxalate stones due to a heavy 
urinary concentration in oxalate (enteric hyperoxaluria) 
[108, 109]. Free fatty acids resulting from malabsorption 
chelate calcium ions in the intestinal lumen and oxalate 
ions are therefore no more bound to calcium ions and 
absorbed through the colonic lumen [110]. Kidney stones 
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resulting from enteric malabsorption are typically made 
of calcium oxalate monohydrate and have a specific mor-
phology: light brown aspect and poorly organized section 
(type Ie). This morphology is specifically associated to 
massive hyperoxaluria and high oxalate/calcium ratio in 
the urine [34].
Urological management of kidney stones
Nowadays there are three most used surgical procedures in 
the treatment of urinary stones which are shockwave litho-
tripsy, ureteroscopy and percutaneous nephrolithotomy.
Extracorporeal shock wave lithotripsy (ESWL) is a mini-
mal invasive treatment based on shockwaves that are focused 
on a target (the stone). The success rate of ESWL said Dr 
Johanna Noels from Urology department, University hos-
pital Brugmann in Brussels, Belgium, is influenced by the 
stone localization and anatomical factors of the kidney and 
ureter, the hardness of the stone which is estimated by meas-
urement of Hounsfield units (HU) on CT-images, (exception 
cystine stones with low HU, but very resistant), the stone 
size and patient factors (obesity) and preference of patients 
[111].
Ureteroscopy is nowadays a common procedure to treat 
ureteral and kidney stones said Dr Carl Van Haute from 
Urology department, University hospital Brugmann in 
Brussels, Belgium. This minimal invasive endo-urological 
procedure has several advantages such as high stone-free 
rate (SFR) with a minimal risk of complications. Indica-
tions of ureteroscopy were highlighted. Semi-rigid ure-
teroscopy is used to treat a ureteral stone, mostly in the 
middle and lower parts of the ureter, whereas flexible ure-
teroscopy can be used to treat any ureteral stone, as well 
as kidney stones (upper, mid and lower pole stones). Stone 
size, stone location and degree of impaction can influence 
SFR. Stone composition on the other hand won’t affect 
SFR but will lead to longer operative times.
Whether a stone should be completely dusted to achieve 
the highest SFR, or fragmented with successive extraction, 
is still controversial. Complication rate is very low (3.5%) 
and complications are mostly minor. Severe complications, 
such as ureteral trauma (0–2%) and urinary sepsis with 
multi organ failure are rare (0.1%).
Percutaneous nephrolithotomy (PCNL) is the old-
est minimal invasive treatment strategy to treat large 
kidney stones. PCNL can be used to treat large kidney 
stones (> 10 mm), staghorn stones, infection stones, and 
large or impacted proximal ureteral stones. In case of a 
retrograde inaccessible urinary derivation (ileal conduit, 
neobladder, continent urinary reservoirs, etc.), PCNL is 
a treatment option for kidney and ureteral stones. Among 
minimally invasive techniques for kidney stones (ESWL/
URS), PCNL has definitively the highest SFR for large 
stones (> 2 cm).
When performing PCNL, obtaining adequate renal access 
is the key factor. Different imaging methods are used such as 
ultrasound, fluoroscopy, CT and endoscopy guidance.
PCNL can be performed in prone or supine position. Both 
positions have benefits and drawbacks, the choice for either 
position depends on the surgeon’s experience, patient-related 
factors and stone burden.
Modern PCNL techniques include miniaturization of 
the surgical devices, aiming at less blood loss, less renal 
damage, and less pain. Standard, mini, ultra-mini, super-
mini, mini-micro and micro techniques have been described, 
all with varying tract sizes (< 5 french up to > 22 french). 
Smaller tracts lead to less blood loss, less pain and shorter 
Table 3  Considerations in special populations regarding risks associated with calcium and vitamin D supplementation
Generally, dietary sources of calcium are preferred over supplemental (tablet) in patients whose calcium intake is below the recommended daily 
intake. The following additional considerations/risk factors should be considered
Population Consideration/risk
Menopause, elderly Impaired intestinal calcium absorption
Achlorhydria, malabsorption Impaired calcium absorption. Calcium from natural sources are preferred 
over calcium supplementation. Calcium citrate recommended as calcium 
supplement given its optimal intestinal bioavailbility and it may slightly 
increase urinary citrate excretion
Obese Higher baseline bone mineral density, but also CV risk
Advanced CKD Vascular calcification with greater calcium supplementation
Genetics/Race Lower urine calcium in Blacks vs. Whites
Risk of hypercalciuria/stones with calcium and/or vitamin D supplementation 
in idiopathic infantile hypercalcemia (mutations in CYP24A1, SLC34A1)
1α hydroxylase over-activity (primary hyperparathyroidism, 
sarcoidosis, others…)
Risk of hypercalciuria/stones with calcium and/or vitamin D supplementation
“Absorptive hypercalciuria” Risk of hypercalciuria/stones with calcium and/or vitamin D supplementation
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hospital stays, but have a negative impact on the operative 
time.
Complications in PCNL can occur. Infectious complica-
tions (10%) and bleeding (7%) are the most frequent. Injury 
to nearby organs (pleura, liver, spleen, colon, etc...) are rare 
(1%) and can sometimes need to be conservatively managed.
Epidemiology of urolithiasis in Belgium 
according to Daudon’s morphoconstitutional 
classification
Increasing evidence underlines that morphoconstitutional 
(MC) analysis is a clue to the pathogenesis of KS and guides 
preventive and therapeutic specific interventions.
Dr Romy Gadisseur from Clinical Chemist, EuSpLM, 
Laboratories “Emergency, Allergy, Urolithiasis” at Univer-
sity Hospital of Liège and Vincent Castiglione Ph.D. student 
at the Clinical Chemistry department of University Hospital 
of Liège presented their results of distribution of stone com-
position in Province of Liège (Belgium) according to age 
and sex [112]. They retrospectively reviewed 1869 urinary 
stones analyzed between 2010 and 2013 at the laboratory 
of the CHU of Liège (Belgium). Samples were assessed by 
infrared spectroscopy, and morphology was used to clas-
sify KS in MC types according to Daudon’s classification. 
Among 1869 stones, 69.2% affected men. The peak preva-
lence was observed between 50 and 60 years of age in both 
genders. The main constituent was calcium oxalate monohy-
drate (54.4%), mainly organized as type Ia (94%). Calcium 
oxalate dihydrate was found in 19.8% samples, with an equal 
distribution between types IIa and IIb. Uric acid was the 
3rd most frequent constituent in men (10.8%), instead of 
phosphates in women (26.6%). Urinary infection may be the 
main cause of stone formation in 6% of patients. Multiple 
morphological types were concomitantly identified in 49.3% 
of stones. With aging, the proportion of calcium oxalate 
dihydrate stones decreased, while that of calcium oxalate 
monohydrate and uric acid increased in both genders.
Prof Fredric Cotton and Agnieszka Pozdzik presented 
data from retrospective study applying Daudon’s MC classi-
fication based on stereomicroscopy and infrared spectropho-
tometry analysis of KS inform the center in Brussels. The 
analysis was carried out on 5480 samples sent to the labora-
tory between 2007 and 2013. Among 5027 stones formers, 
3549 (71%) were men and 1478 (29%) were women. The 
main compound observed was calcium oxalate (whewel-
lite 52%, weddellite 23%), followed by calcium phosphate 
stones (carbapatite 6.8%), uric acid stones (anhydrous uric 
acid 9.1%), and struvite (2.1%). In 40% of the cases, one 
single compound accounted for more than 90% of the com-
position. Two compounds or more were found in 28% and 
31% of KS, respectively. The most common associations 
were weddellite-whewellite-carbapatite (15%), weddellite-
whewellite (12.4%) and weddellite-carbapatite (6.1%).
Type Ia was the most common in whewellite stones 
(91.6%) and type IIa (73%) followed by type IIb (25%) in 
weddellite stones. Uric acid stones corresponded mainly to 
type IIIa (52%) and IIIb (46%). Carbapatite defined as type 
IVa was found in 42% and as type IVb in 32%. Whewellite 
and weddellite KS predominated in men in all age groups 
with the highest prevalence between 40 and 50 years. The 
prevalence of uric acid KS was higher in men peaked 
between 60 and 70 years. Struvite and carbapatite KS were 
mostly observed between 40 and 50 in both genders but 
more frequently in women between 20 and 60 years. To 
our knowledge, the epidemiology based on M-C analysis 
reported here has been performed in the largest cohort of 
KS available in Belgium. Presented data suggests that the 
leading metabolic disorders involved in lithogenesis in the 
Brussels population are likely intermittent hyperoxaluria 
leading to stones of type Ia and hypercalciuria associated 
with stones of type IIa.
Medical measures for the secondary 
prevention of nephrolithiasis
Kidney stone disease without treatment is a recurrent illness 
that represents a major health burden across the globe with 
associated economic costs. A conservative approach is the 
key management in all KSF. Pharmacological treatment is 
indicated in recurrent stone-forming populations [113].
High oral fluid intake must be consumed in all KSF to 
reduce urinary saturation with respect to stone-forming salts 
[114]. The consumption of fructose- and phosphoric acid-
based soft drinks may increase the risk of KS formation.
A dietary intervention consisting of low sodium 
(≤ 100 mEq/day), low animal protein (50 to 60 g/day) with 
normal calcium intake (1200 mg/day) significantly reduced 
risk of KS recurrence when compared to low dietary calcium 
intake (400 mg/day) [113]. However, the role of the low 
animal protein intake alone on reducing stone recurrence has 
been shown only in one study. Similarly, the evidence for the 
role of dietary fiber, low sodium, calcium and purine intake 
in the recurrence of KS remains circumstantial.
Pharmacological treatment of calcium KSF includes 
alkali and thiazide diuretics [115, 116]. Alkali treatment 
is recommended in recurrent calcium oxalate and calcium 
phosphates as well as UA kidney stone formers, with hypoci-
traturia or normal urine citrate, distal renal tubular acidosis, 
chronic diarrhea, drug or diet-induced hypocitraturia. Thi-
azide diuretics are commonly used in those with hypercal-
ciuric nephrolithiasis. It is preferable to combine potassium 
alkali treatment with thiazide than potassium chloride sup-
plementation in raising urinary citrate excretion [116].
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Allopurinol was shown to be effective in lowering the 
risk of calcium KS. The effectiveness of the magnesium in 
reducing the risk of stone has not yet been established.
Challenges in the diagnosis of kidney stones
With careful evaluation and management, the great major-
ity of KS are preventable. Despite vast developments in the 
radiological, morphoconstitutional and biochemical analyses 
in the past 5 decades, the incidence, costs, and morbidity of 
nephrolithiasis are rising, and persistent challenges hinder 
the optimal diagnosis and KSD management. In particu-
lar, recent advances in imaging techniques to identify stone 
composition and/or extent of Randall’s plaque in vivo are 
promising. Challenges in biochemical analyses of individual 
urinary parameters, and in computer-based assessment of 
urinary saturation indices, include a significant overlap in 
these parameters between stone formers and non-stone form-
ers. Cut-off values for predicting stone recurrence are cur-
rently investigated. The morphoconstitutional analysis of KS 
needs to be more frequently used as it can be very helpful 
in the evaluation of KS etiology considering the fact the KS 
contain the fingerprints of metabolic disorders.
Conclusions and outcomes
The symposium on kidney stones and mineral metabolism 
is currently one of the few dedicated kidney stones meetings 
to be held internationally on a biannual basis. In 2017, the 
first meeting brought together clinical and basic researchers, 
pathologists, nephrologists, urologists and biologists. This 
model demonstrates how clinical and research collabora-
tion should be facilitated, as it brings together worldwide 
recognized experts in the diagnosis and treatment of neph-
rolithiasis. This is of greatest importance for patients and 
families, specifically those with inherited KSD, as well as to 
encourage new recruitment of physicians interested in KSD 
pathophysiology. The symposium provided the available 
knowledge in KSD but also the future direction in promot-
ing the new advancements in the field.
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